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Transcranial magnetic stimulation for migraine:
clinical effects






Abstract The objective was to
assess the impact of transcranial
magnetic stimulation (TMS) on
pain and the autonomic nervous
system (ANS) in migraine. Forty-
two people [mean age 41.43±11.69
(SD) years, 36 females] were ran-
domised into high vs. low TMS
stimulation groups and received 2
brief pulses of TMS. Thirty-three
(33/42) individuals had heart-rate
variability assessed, before and
after stimulation. No group effects
were found. Pain decreased by 75%;
32% of people after 1 treatment
reported no headache after 24 h.
Mean heart rate decreased from
79.05±10.27 to 72.89±11.35
beats/min. The low-frequency (LF)
and the high-frequency (HF) areas
derived from power spectral analy-
ses increased [mean 6522±1277 to
8315±1009 beats/min2 (LF)
(p=0.001) and mean 5600±1568 to
8755±3071 beats/min2 (HF)
(p=0.001)]. The LF:HF ratio
decreased from mean 1.31±0.51 to
1.13±0.48 (NS). TMS produces
immediate, sustained reductions in
pain and modification of the ANS.
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Burden of illness and patient satisfaction reports in migraine
headache show that current treatment regimes are incomplete
[1, 2]. The main patient concerns are that (a) relief of pain is
not immediate or sustained, (b) potential drug side effects are
worrisome, and (c) the frequency of headache recurrence is
not abolished or significantly diminished. As at least 10% of
the population worldwide suffers from migraine headache,
the impact of these problems is significant [3]. More effec-
tive treatment regimes and a complete understanding of the
pathophysiology of migraine are needed.
Controversial theories about the cause and mecha-
nisms of migraine range from experiments that show
impaired brain energy metabolism [4], autonomic nervous
system (ANS) hypofunction [5, 6], brain cell hyperex-
citability to low intracellular brain magnesium [7–15].
Once considered solely a vascular event, current research
supports a combination of both neural and vascular caus-
es [16–20]. Many studies report the biochemical reaction
and clinical effects of medications in migraine [21].
Despite considerable study, a unified theory of the patho-
physiology of migraine does not exist. The most current cor-
tical depression theories argue that the spreading depression
of Leão is related to glutamate changes within the brain.
This mechanism may not apply to all forms of migraine, and
studies of cortical excitability of migraine done between
migraine attacks yield conflicting results concerning the
hypo- and hyperexcitability of the cortex [22–33]. Because
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both pharmacological and non-pharmacological treatment
interventions only partly address patient concerns, a novel
treatment method using single-pulse transcranial magnetic
stimulation (TMS) was evaluated.
Justification for the application of TMS
TMS involves the application of a large brief current that
is passed through an insulated coil placed on the scalp.
The current sets up a magnetic field that penetrates the
skull producing a secondary current that stimulates the
cerebral cortex as well as trigeminal nerve fibres. This
secondary current alters the cortical excitability.
Theoretical mechanisms of the relationship between
migraine headache with aura and TMS are that just before
the headache begins, brain cells become overly active and
form a wave of increased neuronal activity. The travelling
wave of hyperactive cells spreads across the cortex followed
by an area of depressed neuronal activity. The effect of this
process may be the occurrence of an aura, pain, sensory
changes in the face and/or limbs, and/or nausea and dizzi-
ness, through activation of the trigeminal-vascular system
and the trigeminal-cervical complex [34]. It is hypothesised
that if very short pulses (1 ms) of TMS are applied to the
scalp just as the headache begins, these pulses stop the trav-
elling wave of hyperactive brain cells and subsequent neu-
ronal depression. The headache either stops or it is less
severe. Repeated applications may result in a decrease in
headache frequency or complete cessation of headache.
Safety data indicate that single-pulse transcranial stimu-
lation is a safe, useful tool for investigating neurophysiolog-
ical mechanisms in human studies. No adverse side effects
with single-pulse stimulation have been reported [35, 36].
We report the results of a study to assess the efficacy
of TMS on pain intensity and heart-rate variability (HRV)
in individuals with migraine headache.
This project was approved by the Research Ethics
Committee of the Hamilton Health Sciences Centre, Hamilton,
Ontario, Canada. An information package was provided
and informed consent was obtained from all participants,




Eighty (80) people from the community-at-large were screened
for admission to the study. All individuals had been previously
diagnosed with migraine and were re-assessed at intake.
Forty-two (42) individuals with migraine (ICHD-II classification)
met the inclusion criteria [37]. One of the criterion was that individ-
uals must live and/or work within 30 min of our laboratory. This fac-
tor was important because it was necessary to apply the stimulation
as soon as possible. Exclusion criteria were metal in the cranium,
cardiac/neuro pacemakers, previous seizure activity, neurosurgery or
head injury. Ten (10) people had migraine with aura, 25 without aura
and 6 had headache with migraine components. The average
headache duration was 8.84±14.65 (SD) h. Headache pain persisted,
on average, from 20 min to 10 days. The shortest episode was 10
min and the longest 31 days. Headache frequency ranged from 1/day
to 4/year. In 25 patients precipitating factors were unknown. In the
remaining patients (n=17), hormonal changes (n=6), stress (n=2),
head injury (n=3) and food sensitivities (n=2) were thought to be
precipitating factors for migraine. Fourteen people reported onset of
headache in the morning, 11 people reported the afternoon as time of
occurrence and 17 were unable to define a pattern of onset. Patients
(mean age of 41.42±11.69 years, 36/42 females) were randomised
into either the high stimulation (50% of the maximum output) or low
stimulation (30% maximum output) group. Of those individuals who
received stimulation, five people had an aura and three of the five
had pain with an aura. There were 19 complaints of pain in the tem-
poral region, 24 in the occipital area and 8 in the frontal area of the
brain. Nine out of 51 complaints were in more than one area. Other
signs and symptoms were nausea, double vision, photophobia, aura
and dizziness. Headache diaries were kept pre- and post-stimulation.
There were no restrictions on medications, which consisted of anal-
gesics, narcotics, antiemetics and/or sedatives.
Measurements
Stimulation parameters
TMS was applied using a Caldwell Stimulator, model #MES-10.
The stimulator was programmed to deliver a pulse of 70 µsec
width. The coil radius was 9.5 cm. Peak induced voltage was
187 V. The magnetic intensity in the middle of the coil was 2.3 T.
TMS was applied as soon as possible on arrival in the laborato-
ry. Each person received two brief pulses, 5 s apart, over the area
of perceived pain or over the area of the brain generating the
aura. Patients and examiners were blinded as to the intensity of
the stimulation (high vs. low). Forty-two people received 1 trial,
22/42 had 2 trials and 11/42 people had 3 trials. No person
received more than 3 impulses of TMS at any given time. Repeat
trials remained at the initial stimulation intensities. Follow-up
calls were made to individuals 24 h after stimulation.
Pain and suffering measures
Pain intensity was measured using a 5-point Likert-type scale in
which 5 was the worst response. Pain levels were recorded pre-
stimulation, and at post-stimulation at 5-min intervals for 20
min. Suffering was assessed using the Measuring and Assessing
Suffering Questionnaire (MASQ) on intake to identify the suf-
fering component [38].
Heart-rate variability measures
Thirty-three (33/42) individuals were assessed for ANS effects
using HRV measures. Nine people who were part of the pilot
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study were not assessed for HRV. HRV was measured 5 min
before stimulation and for 20 min post-stimulation. The HRV sig-
nal was computed from the electrocardiogram (ECG) and sub-
jected to spectral analyses. Areas under the low-frequency (LF)
and high-frequency (HF) components of the HRV were deter-
mined and a ratio of the powers (LF:HF area) was calculated.
Signal processing of heart rate variability
Processing the HRV was done as follows. A continuous ECG signal
was obtained from the lead II electrodes, amplified and sampled at
500 times/s and stored on a hard disk [39]. The stimulation did not
generate any ectopic beats. Off-line analysis of the power spectra of
the heart rate (HR) was performed. Following QRS detection, the
HR signals of 128 s were interpolated using linear interpolation
every 0.5 s. The re-sampled HRV signal was passed through a 4th-
order high-pass IIR filter with a cut-off frequency of 0.02 Hz to
remove the very low frequency components. Subsequently, an 11th-
order autoregressive model was fitted to the signal and power spec-
tra were computed using the autoregressive modelling method.
Following normalisation, percentage areas in the LF band and the
HF band were computed. The LF band was from 0.02 to 0.15 Hz
while the HF band extended from 0.15 to 0.4 Hz. The LF band is
predominantly sympathetic and the HF band is vagally modulated
[40]. A ratio of the LF:HF ratio was computed before and after stim-
ulation. All results are expressed as mean±SD.
Statistical analyses
Analyses of variance techniques were applied to determine
whether there were differences between the high- and low-stimu-
lation groups. A repeated measures of covariance design was used
to assess the mean difference in a Likert scale pain “score”. The
4 paired observations for each study participant high vs. low
(minute 5, 10, 15, 20) could effectively use each subject as
his/her own control. A further specification (that of a covariate
which remained constant across trials) was used to adjust for pre-
intervention pain. The repeated measures ANOVA also originally
included a between-subjects grouping factor of stimulation group
(high vs. low intensity). The mean HR and indices derived from
the power spectrum of the HRV were subjected to Student’s t-test
to determine if there was a significant difference before and after
stimulation. A minimum level of significance was set at p<0.05.
Results
High vs. low stimulation
The mean differences between the low-stimulation and
high-stimulation groups were found to be slight, even
after adjusting for baseline (pre-intervention) pain. The
interaction term for stimulation group by time (minute 5
to minute 20 post-stimulation) was not statistically signif-
icant. An apparent (albeit non-significant) linear trend was
still found for a main reduction in pain from minute 5 to
minute 20 post-stimulation. Further, data exploration
revealed few outliers in either stimulation group.
Subsequently, the high- and low-stimulation groups were
combined into one group for further comparisons.
Pain and suffering
There was an overall mean decrease in pain intensity of
75% which was calculated based on the change between
the pre-stimulation mean of pain intensity, 3.30±0.74, and
the post-stimulation value, 2.49±1.01 (p<0.05). At the
intake assessment there were no significant differences in
total suffering scores between those persons with pain
(n=19) and those without (n=23). In the pain group, mean
values for total suffering were 2.24±0.54 vs. 2.36±0.573
SD for the no-pain group.
Autonomic nervous system effects
ANS effects were significant. Mean HR decreased from
79.05±10.27 to 72.89±11.35 beats/min. The LF area
increased from 6522±1277 to 8315±1009 beats/min2
(p<0.001), and the HF area increased from 5600±1568 to
8755±3071 beats/min2 (p<0.001). The LF:HF ratio
decreased from 1.31±0.51 to 1.13±0.48 (NS). An example
of the power spectrum before and immediately after TMS,
in one subject, is shown in Figures 1 and 2.
Fig. 1 A segment of the continuous heart-rate variability data of a
patient during migraine. The length of the recorded HRV is approx-




Sixty-nine percent of the people showed improvement
with 1 trial, 87% improved in those persons who had 2 tri-
als and 82% got better after 3 trials. In individuals with an
aura, relief was 100% and immediate. The mean time to
show improvement was 15.46±6.82 min. Improvement
was defined as a decrease in perception of pain of at least
1 level on a 5-point Likert-type scale, and as a decrease in
the number of headaches occurring after TMS.
Of those persons who received 1 trial (n=42), 32%
reported no further headache after 24 h. After 2 trials
(n=22), 29% were headache free the next day and in
those persons (n=11) who had 3 trials, 40% reported no
further headaches after 24 h (see Table 1). Of those per-
sons without an aura who received 1 trial, 6 patients
were headache free, of those who had 2 trials, 8 were
headache free and after 3 trials, 1 was headache free
after 20 min.
Seventy-six percent of patients who received 1 trial did
not take medications before stimulation. Twenty-four per-
cent did not take medication in the following 24 h. In the
2-trials group, 52% did not take medication prior to stimu-
lation and 35% did not take rescue medication for 24 h. For
the group who received 3 trials, 55% did not take medica-
tion pre-stimulation and 60% did not take it for 24 h.
Side effects
No adverse side effects were reported either immediately
post-treatment or after 24 h. Only 1 person reported slight
unsustained dizziness and 1 person was a little drowsy.
Several people reported feeling more energetic while oth-
ers reported longer than usual times between headache
onset. Two people said they felt tired after treatment. For
those who did not receive immediate benefit with only 1
trial, reports were that there was difficulty controlling the
persisting headache with their usual treatments. None of
these effects were recurring or required medical attention.
Discussion
TMS is an important adjunct treatment for migraine
headache. Pain relief is often immediate and frequency of
headache recurrence decreased by 48% after 1 trial with
no adverse side effects. Reports of improvement after
more than 1 trial may be due to a cumulative effect of
TMS. Further studies are needed.
Processing the HRV signals makes a significant contri-
bution to the understanding of the role of the ANS in
migraine. During the study we observed that TMS provid-
ed reduction in the pain. Our goal was to assess the effect
of such changes objectively using PS/HRV. If one reduces
the pain, there may be changes in the sympathetic–vagal
balance of the ANS. Future studies are needed to compare
the effects on the ANS between TMS and other interven-
tions such as pharmacological agents.
Further, Appel et al. [40] report an enhancement of LF
power and suggest that this finding is due to vagal nerve
overflow to the sinus node, indicating that patients with
migraine have sympathetic system instability. Our study
shows that TMS produces perturbations of the ANS,
which results in a balancing of the sympathetic and
parasympathetic components. TMS may “normalise” the
ANS and subsequently modify the vasodilatation of the
meningeal blood vessels. These observations support the
work of Silberstein [17], Goadsby [19] and Matharu et al.
[13], who argue that balancing the ANS may not only pre-
vent abnormal sensory neuron activation in the trigeminal
Table 1 TMS and headache recurrence after 24 h
Trials Headache recurrence
None Mild Moderate Severe
1 (n=42) 32% 24% 11% 33%
2 (n=22) 29% 16% 8% 46%
3 (n=11) 40% 30% 0% 30%
Results suggest that the effects of TMS may be cumulative
Fig. 2 Depicts the heart-rate variability signal of a patient follow-
ing transcranial magnetic stimulation. The power spectrum of the
first 128 s of the HRV signal is plotted. The mean heart rate shows
a slight downward trend. However, note the increase in power in
both LF and HF bands of the power spectrum
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nucleus caudalis, a process thought to be the cause of the
phenomenon of cutaneous allodynia, but it may also have
a damping effect on central nervous system hyperactivity
and thereby abort the headache.
The relationship between TMS and headache medica-
tions also requires further investigation. Although 76% of
individuals who received TMS did not take medication
prior to treatment and 24% did not take medications post-
treatment, the relationship between TMS and specific
drug regimes must be rigorously delineated [41, 42].
One limitation of the study is that it was hypothesised
that the low stimulation group would show no effect and
as a result would act as a control group. As there is an
effect in both groups, stimulation/sham stimulation stud-
ies are being done. Optimal stimulation intensities are
now possible with the advent of newer stimulation
devices. Patients and investigators are blind as to whether
stimulation is being delivered or not. To explore the issue
of placebo more rigorously, patients are initially asked
whether they think they are in the stimulation or non-stim-
ulation group and are questioned again after the interven-
tion is applied. Results are pending.
A second limitation to the study is that patients were
required to come to the laboratory and sometimes, by the
time they arrived, the aura had disappeared and the
headache was well established. A portable device has been
developed to overcome this problem and it is currently
being tested. We believe that further episodes of stimula-
tion could have achieved better control of headache.
Availability of the portable device will allow testing of
this hypothesis.
Preliminary intake results also provide evidence that
the phenomenon of suffering, in association with migraine
headache, is separate from pain. These results confirm
findings in other chronic illnesses (arthritis) [38].
Suffering is an issue to be addressed if optimal care in
migraine is to be achieved. Perceptions of suffering were
the same for those who had pain as those who did not.
Follow-up measures of suffering, post-stimulation, would
be useful and are incorporated into our new protocol.
To date, our initial results provide evidence that TMS
can prevent headache and is an effective adjunct treatment
for migraine headache pain. TMS meets the criteria of
immediate, sustained pain relief with no known side
effects. TMS produces a balancing of the sympathetic and
parasympathetic components of the ANS.
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